{"id":"placebo-evogliptin","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypoglycemia"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DPP-4 inhibitors work by blocking the action of the enzyme DPP-4, which breaks down incretin hormones. This leads to increased levels of incretin hormones, which in turn increases insulin release in response to meals and decreases glucagon levels in the circulation during the postprandial period.","oneSentence":"Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:58.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05143177","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)","status":"SUSPENDED","sponsor":"REDNVIA Co., Ltd.","startDate":"2022-06-27","conditions":"Calcific Aortic Valve Disease","enrollment":580},{"nctId":"NCT04356742","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-05-26","conditions":"Type 2 Diabetes","enrollment":198},{"nctId":"NCT04170998","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-01-02","conditions":"Type2 Diabetes","enrollment":283},{"nctId":"NCT03910361","phase":"PHASE4","title":"Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-04-12","conditions":"Type2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":51},{"nctId":"NCT02689362","phase":"PHASE2","title":"Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2017-08-08","conditions":"Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT02974504","phase":"PHASE4","title":"Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-09","conditions":"Type2 Diabetes","enrollment":207},{"nctId":"NCT02946541","phase":"PHASE3","title":"A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":160},{"nctId":"NCT02949193","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo Evogliptin","genericName":"Placebo Evogliptin","companyName":"Eurofarma Laboratorios S.A.","companyId":"eurofarma-laboratorios-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Evogliptin is a small molecule dipeptidyl peptidase IV inhibitor used to treat Type 2 Diabetes. It is classified as an INHIBITOR drug class, specifically targeting the Dipeptidyl peptidase 4 molecular target.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}